Company

Nurix Therapeutics

Pharmaceutical intelligence for Nurix Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

CompetitiveJuly 5, 2026

Nurix Therapeutics initiates NX-5948 study for relapsed CLL/SLL post-BTK and BCL-2 therapy

Nurix Therapeutics is conducting a trial for NX-5948 in patients with relapsed/refractory CLL/SLL who have previously been treated with BTK and BCL-2 inhibitors.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity

No signals indexed for this entity yet.

Competitive activity(1)

CompetitiveJuly 5, 2026

Nurix Therapeutics initiates NX-5948 study for relapsed CLL/SLL post-BTK and BCL-2 therapy

Nurix Therapeutics is conducting a trial for NX-5948 in patients with relapsed/refractory CLL/SLL who have previously been treated with BTK and BCL-2 inhibitors.

Assets

Nurix →

Therapeutic areas

CLL →

Oncology →

SLL →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.